PREVALENCE AND CHARACTERIZATION OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER IN **SPAIN: THE CARPE-DIO STUDY.**



Concepción Pérez Hernández¹, Ana Blasco Cordellat², Álvaro Gándara del Castillo³, Ana Mañas Rueda⁴, Manuel Jesús Rodríguez López⁵, Vicente Martínez⁶, Ana Sánchez-Gabriel⁶, Carmen Montoto⁶, CARPE-DIO study group.

¹Hospital Universitario La Princesa, Pain Unit, Madrid; ²Hospital General Universitario de Valencia, CIBERONC, Medical Oncology, Valencia; ³Hospital Universitario Fundación Jiménez Díaz, Palliative Care Unit, Madrid; ⁴Hospital Universitario La Paz, Radiation Oncology, Madrid; ⁵Hospital Regional Universitario Carlos Haya, Pain Unit, Málaga; ⁶Takeda Farmacéutica España, Medical Department, Madrid. Spain.

Background


- Breakthrough pain (BTP) is a common problem encountered in clinical practice in patients with cancer, has a heterogeneous clinical presentation, and is associated with an important impact on the patient, family, caregivers and society.
- The clinical picture of BTP varies greatly from patient to patient. In a European study conducted in 1.000 patients with cancer, 44% had incident pain, 41.5% had spontaneous pain and 14.5% had a combination of both forms of presentation¹.
- · Age, type of cancer, performance status, background pain intensity, and mechanism are among the factors affecting the clinical presentation of BTP².
- Information on the prevalence and clinical characteristics of BTP in Spain is very limited.

Study Objectives

- Primary objective: To evaluate the prevalence of BTP in patients with cancer attending the main specialties diagnosis involved in the and management of BTP in Spain.
- Secondary objectives: Describing the clinical characteristics of patients with BTP, and evaluating the impacts on daily activities and quality of life (through Alberta, BPI and SF-12 questionnaires).

Study Design

observational, cross-sectional, multidisciplinary Multicenter, conducted in the medical oncology, radiation oncology and hematology departments as well as in pain and palliative care units from November 2016 to April 2018.



Study Results

A total of 3765 patients were seen at 32 sites by 43 specialists. Over 1117 patients with cancer-related pain, 539 had BTP (48%, 95%CI, 45% to 51%). In characterization study 207 adult patients with oncologic pain adequately controlled with opioids and meet criteria of BTP (Davies' algorithim) were included.

BTP Characteristics *	Type I N=67 (32.4%)		Type II N=59 (28.5%)		Type III N=31 (15.0%)		Type IV N=47 (22.7%)	
BPI Intensity	4.9	1.6	5.4	1.8	6.3	1.6	5.4	1.9
BPI Interference	5.5	2.2	6.0	1.8	7.9	1.5	5.8	1.9
SF-12 Physical	29.3	8.6	30.1	8.6	25.9	4.5	27.6	7.7
SF-12 Mental	38.9	9.2	35.8	9.1	31.0	8.7	39.1	9.7



Pain qualitatively description	N	%
Stabbing	113	57.9
Splitting	58	29.7
Sharp	57	29.2
Punishing-Cruel	53	27.2
Heavy	52	26.7
Hot-Burning	50	25.6
Fearful	42	21.5

Pain intensity *	N	%	
Mild	3	1.5	
Moderate	31	15.9	
Severe	160	82.1	

^{*} Alberta Q4: Pain intensity

References

- 1. Davies et al. J Pain Symptom Manag. 2013.
- 2. Mercadante et al. Cancers (Basel). 2018.
- 3. Deadrea et al. J Pain Symptom Manag. 2013.

Relationship to baseline pain* N % Brief flare up of baseline pain 101 53.2 Different from baseline pain 69 36.3 Not sure 20 10.5


* Alberta Q1: Relationship to baseline pain

Type of Breaktrhrough Pain

intensity

BCP type I

N=67 (32.4%)



Conclusions

- In the Spanish setting there is a high prevalence of BTP among patients exhibiting cancer-related pain.
- BTP is heterogeneous, and therefore cannot be considered as a single entity, it needs an early detection and should be investigated and characterized in every patient with cancer pain in order to provide orientation for pain management.

Acknowledgments

- This study was funded by Takeda Farmacéutica España S.A.
- The authors thank APICES for the project management, monitoring, data management, statistical analysis and medical writing.





BCP type II

N=59 (28.5%)

Contact: Concepción Pérez Hernandez, Hospital La Princesa, Pain Unit. concha.phte@gmail.com.